AU2015241373B2 - Methods of treating nail and scalp psoriasis - Google Patents

Methods of treating nail and scalp psoriasis Download PDF

Info

Publication number
AU2015241373B2
AU2015241373B2 AU2015241373A AU2015241373A AU2015241373B2 AU 2015241373 B2 AU2015241373 B2 AU 2015241373B2 AU 2015241373 A AU2015241373 A AU 2015241373A AU 2015241373 A AU2015241373 A AU 2015241373A AU 2015241373 B2 AU2015241373 B2 AU 2015241373B2
Authority
AU
Australia
Prior art keywords
antibody
psoriasis
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015241373A
Other languages
English (en)
Other versions
AU2015241373A1 (en
Inventor
Paul KLEKOTKA
Gregory KRICORIAN
Hiroki MATSUDO
Hidemi Nakagawa
Ajay Nirula
Kenji OHTAKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Amgen K A Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen K A Inc filed Critical Amgen K A Inc
Publication of AU2015241373A1 publication Critical patent/AU2015241373A1/en
Assigned to AMGEN K-A, INC. reassignment AMGEN K-A, INC. Amend patent request/document other than specification (104) Assignors: KIRIN-AMGEN, INC.
Application granted granted Critical
Publication of AU2015241373B2 publication Critical patent/AU2015241373B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AU2015241373A 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis Active AU2015241373B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461972638P 2014-03-31 2014-03-31
US61/972,638 2014-03-31
US201462031850P 2014-07-31 2014-07-31
US62/031,850 2014-07-31
US201462041879P 2014-08-26 2014-08-26
US62/041,879 2014-08-26
PCT/US2015/021613 WO2015153144A1 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Publications (2)

Publication Number Publication Date
AU2015241373A1 AU2015241373A1 (en) 2016-10-06
AU2015241373B2 true AU2015241373B2 (en) 2020-11-05

Family

ID=52808190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015241373A Active AU2015241373B2 (en) 2014-03-31 2015-03-19 Methods of treating nail and scalp psoriasis

Country Status (11)

Country Link
US (1) US20170174772A1 (cg-RX-API-DMAC7.html)
EP (1) EP3126392B1 (cg-RX-API-DMAC7.html)
JP (1) JP6596014B2 (cg-RX-API-DMAC7.html)
KR (2) KR102530900B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456751B (cg-RX-API-DMAC7.html)
AU (1) AU2015241373B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944605C (cg-RX-API-DMAC7.html)
ES (1) ES2760002T3 (cg-RX-API-DMAC7.html)
MY (1) MY184189A (cg-RX-API-DMAC7.html)
SG (1) SG11201607881SA (cg-RX-API-DMAC7.html)
WO (1) WO2015153144A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
PT3295957T (pt) 2010-01-15 2019-11-12 Kirin Amgen Inc Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase
CN105534996B (zh) * 2016-02-24 2018-05-01 长沙佰顺生物科技有限公司 一种治疗银屑病的药物组合物
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
JP7033774B2 (ja) * 2017-08-25 2022-03-11 国立大学法人 東京大学 抗サイトカイン抗体療法
CN111670036B (zh) * 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
CA3091598A1 (en) 2018-02-22 2019-08-29 Tokai University Educational System Il-17a activity inhibitor and use thereof
JOP20210229A1 (ar) 2019-02-18 2023-01-30 Lilly Co Eli صيغة جسم مضاد علاجي
JP2022547678A (ja) * 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Ｉｌ－１７ｒａ抗体を用いた非アルコール性脂肪性肝疾患（ｎａｆｌｄ）の治療方法
CN114423455A (zh) * 2019-09-25 2022-04-29 国立大学法人东京大学 用于治疗系统性硬化症的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088120A1 (en) * 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE3922089A1 (de) 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JPH03127800A (ja) 1989-10-13 1991-05-30 Teijin Ltd 腫瘍壊死因子活性抑制物質
JPH0578396A (ja) 1989-12-13 1993-03-30 Yeda Res & Dev Co Ltd ヒト腫瘍壊死因子結合蛋白
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
WO1992013095A1 (en) 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
EP1239043A3 (en) 1992-03-30 2003-01-02 Immunex Corporation Fusion proteins comprising tumour necrosis factor receptor
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JPH05312248A (ja) 1992-05-08 1993-11-22 Nissan Motor Co Ltd シフトレバー装置
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5869286A (en) 1995-03-23 1999-02-09 Immunex Corporation Receptor that binds IL-17
US7030565B2 (en) 2004-07-27 2006-04-18 Jerrell Penn Hollaway Lamp control circuit with selectable color signals
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
UA99716C2 (ru) * 2006-10-02 2012-09-25 Кирин-Амген Инк. Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US9413463B2 (en) 2013-08-30 2016-08-09 Google Inc. Apparatus and method for efficient two-way optical communication where transmitter may interfere with receiver
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088120A1 (en) * 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
WO2012045848A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Methods of treating psoriasis using il-17 antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Anonymous, "NCT02052609 on 2014_01_31: ClinicalTrials.gov Archive", (2014-01-31), URL: https://clinicaltrials.gov/archive/NCT02052609/2014_01_31, (2015-05-13) *
GUDJONSSON ET AL, "HLA-Cw6-Positive and HLA-Cw6-Negative Patients with Psoriasis Vulgaris have Distinct Clinical Features", (2002-02-01), URL: http://www.nature.com/jid/journal/v118/n2/pdf/5601404a.pdf, (2015-10-07) *
KIM A PAPP ET AL, "Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, (2012-03-29), vol. 366, doi:10.1056/NEJMOA1109017, ISSN 0028-4793, pages 1181 - 1189 *
LEONARDI CRAIG ET AL, "Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, (2012-03-29), vol. 366, no. 13, ISSN 0028-4793, pages 1190 - 1199 *

Also Published As

Publication number Publication date
CN106456751A (zh) 2017-02-22
US20170174772A1 (en) 2017-06-22
EP3126392B1 (en) 2019-09-11
WO2015153144A1 (en) 2015-10-08
KR102530900B1 (ko) 2023-05-12
EP3126392A1 (en) 2017-02-08
JP6596014B2 (ja) 2019-10-23
ES2760002T3 (es) 2020-05-12
CA2944605A1 (en) 2015-10-08
JP2017511316A (ja) 2017-04-20
MY184189A (en) 2021-03-24
KR20220093008A (ko) 2022-07-04
CN106456751B (zh) 2021-02-02
SG11201607881SA (en) 2016-10-28
AU2015241373A1 (en) 2016-10-06
CA2944605C (en) 2023-10-17
KR20160130248A (ko) 2016-11-10

Similar Documents

Publication Publication Date Title
AU2015241373B2 (en) Methods of treating nail and scalp psoriasis
RU2707745C2 (ru) Способы лечения или профилактики мигренозной головной боли
JP2022031403A (ja) ＴＧＦβ１結合性免疫グロブリンおよびその使用
CN118924895A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
US10968278B2 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
CN113260385B (zh) 抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
KR20250044949A (ko) 항-조직 인자 항체-약물 접합체 및 암 치료에서의 그의 용도
KR20220158821A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
JP2020519634A (ja) 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
EP4477265A2 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2025504500A (ja) 抗ａｌｋ１抗体およびその使用方法
JP2021088548A (ja) 安定な水性抗体製剤
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025096432A1 (en) Treatment of anca-associated vasculitis
CN118324910A (zh) Ccr8抗体的应用
HK40057787A (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
EA049124B1 (ru) Способы лечения рака с помощью комбинации антитела против vegf и конъюгата антитело против тканевого фактора-лекарственное средство
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AMGEN K-A, INC.

Free format text: FORMER NAME(S): KIRIN-AMGEN, INC.

FGA Letters patent sealed or granted (standard patent)